Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04440774
Recruitment Status : Not yet recruiting
First Posted : June 22, 2020
Last Update Posted : September 24, 2020
Sponsor:
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan area of Monterrey (Mexico), will be recruited as participants

Condition or disease Intervention/treatment Phase
Chikungunya Zika Biological: CHIK low dose Biological: CHIK mid dose Biological: CHIK high dose Biological: ZIKA low dose Biological: ZIKA mid dose Biological: ZIKA high dose Biological: Saline placebo Phase 1

Detailed Description:

This trial consists of 4 intervention arms according to the vaccination product: 1) ChAdOx1 Chik, 2) ChAdOx1 Zika, 3) ChAdOx1 Chik and ChAdOx1 Zika as contralateral co-administration, and 4) placebo. There will be a total of 120 participants divided in ten study groups with 12 participants per group (Table 5.1). Groups 1 to 3 will receive ChAdOx1 Chik + placebo administered contralaterally, Groups 4 to 6 will receive ChAdOx1 Zika + placebo administered contralaterally, and Groups 7 to 9 will receive both ChAdOx1 Chik and ChAdOx1 Zika administered contralaterally. Group 10 will receive placebo in both arms.

Enrolment into this study will be implemented in a step-wise dose escalation manner. Participants will be first recruited into the vaccination groups at the lowest dose (Groups 1, 4 and 7). It is only after completion of these low dose groups and upon satisfactory interim clinical safety reviews that participants will be enrolled into the mid dose groups (Groups 2, 5 and 8). Participants in the high dose groups (Groups 3, 6 and 9) will be enrolled last, after completion and interim clinical safety reviews from the mid dose groups. Participants allocated to the Placebo group (Group 10) will be evenly distributed across the dose escalation model.

Randomisation procedures will be implemented accordingly, at a ratio of 3:3:3:1 for each of the four intervention arms.

The study involves a total of 9 visits (screening inclusive) and follow up will be undertaken for 6 months after vaccination day

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: A Single Centre, Double-blind, Double-dummy Placebo-controlled, Randomised Phase Ib Study to Evaluate the Safety & Immunogenicity of the Candidate Chikungunya Vaccine ChAdOx1 Chik & the Zika Vaccine ChAdOx1 Zika in Healthy Adults in Mexico
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CHIK low dose
Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: CHIK low dose
A single dose of 5x10^9 vp ChAdOx1 Chik

Experimental: CHIK mid dose
Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: CHIK mid dose
A single dose of 2.5x10^10 vp ChAdOx1 Chik

Experimental: CHIK high dose
Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: CHIK high dose
A single dose of 5x10^10 vp ChAdOx1 Chik

Experimental: ZIKA low dose
Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: ZIKA low dose
A single dose of 5x10^9 vp ChAdOx1 Zika

Experimental: ZIKA mid dose
Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: ZIKA mid dose
A single dose of 2.5x10^10 vp ChAdOx1 Zika

Experimental: ZIKA high dose
Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: ZIKA high dose
A single dose of 5x10^10 vp ChAdOx1 Zika

Experimental: CHIK ZIKA low dose
Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: CHIK low dose
A single dose of 5x10^9 vp ChAdOx1 Chik

Biological: ZIKA low dose
A single dose of 5x10^9 vp ChAdOx1 Zika

Experimental: CHIK ZIKA mid dose
Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: CHIK mid dose
A single dose of 2.5x10^10 vp ChAdOx1 Chik

Biological: ZIKA mid dose
A single dose of 2.5x10^10 vp ChAdOx1 Zika

Experimental: CHIK ZIKA high dose
Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: CHIK high dose
A single dose of 5x10^10 vp ChAdOx1 Chik

Biological: ZIKA high dose
A single dose of 5x10^10 vp ChAdOx1 Zika

Placebo Comparator: Placebo
Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
Biological: Saline placebo
A single dose of isotonic saline solution (0.9%)




Primary Outcome Measures :
  1. Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of local reactogenicity signs and symptoms [ Time Frame: 7 days post vaccination ]
    Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination.

  2. Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of solicited systemic reactogenicity signs and symptoms [ Time Frame: 7 days post vaccination ]
    Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.

  3. Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of unsolicited adverse events [ Time Frame: 28 days post vaccination ]
    Occurrence of unsolicited adverse events for 28 days following vaccination

  4. Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants through standard blood tests (full blood count, liver and kidney function tests) [ Time Frame: 28 days post vaccination ]
    Change from baseline for safety laboratory measures (haematology and biochemistry blood results)

  5. Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of serious adverse events during the whole study duration [ Time Frame: 6 months post vaccination ]
    Occurrence of serious adverse events during the whole study duration


Secondary Outcome Measures :
  1. Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via PRNT50 [ Time Frame: 6 months post vaccination ]
    Plaque-reduction neutralisation tests at 50% (PRNT50) against chikungunya and Zika virus.

  2. Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via IgG ELISA antibody titres [ Time Frame: 6 months post vaccination ]
    IgG ELISA antibody titres against proteins of Chikungunya and Zika virus



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy men aged 18 to 50 (inclusive) years at the time of screening.
  2. Healthy women aged 18 to 50 (inclusive) of child-bearing potential who agree to practice continuous effective contraception (see below) during the study and test negative for pregnancy on the day(s) of screening and vaccination.
  3. Are residents of the metropolitan area of Monterrey, Nuevo León.
  4. Provide written informed consent for participation in the study.
  5. Able and willing (in the Investigator's opinion) to comply with all study requirements.
  6. Agreement to inform study team of any impending vaccinations either before or during participation in the study.
  7. Agreement to refrain from blood donation during the course of the study.
  8. Agreement to refrain from receipt of any alphavirus or flavivirus vaccine throughout the duration of the study (e.g. investigational or licensed Yellow Fever, Japanese Encephalitis, Tick Borne Encephalitis or Dengue virus vaccines).

Exclusion Criteria:

  1. Participation in another clinical trial in the 30 days preceding enrolment or during the study period.
  2. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccine, Chikungunya virus vaccine, Zika virus vaccine, Dengue virus vaccine).
  3. Prior receipt of any vaccines administered ≤30 days before enrolment and/or planned during the during the study.
  4. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
  5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
  6. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Any history of anaphylaxis in relation to vaccination.
  7. History of autoimmune disease.
  8. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
  9. Pregnancy, lactation or willingness/intention to become pregnant during the study.
  10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
  11. History of serious psychiatric condition likely to affect participation in the study
  12. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.
  13. Any other serious chronic illness requiring hospital specialist supervision at present or during the last 6 months.
  14. Suspected or known current alcohol abuse. For men, intake greater than 5 drinks on a single occasion or more than 15 drinks per week; and for women, more than 4 drinks on a single occasion or more than 8 drinks per week. One drink =14 grams of pure alcohol.
  15. Suspected or known injecting drug abuse in the 5 years preceding enrolment.
  16. Seropositive for hepatitis B surface antigen (HBsAg).
  17. Seropositive for hepatitis C virus (antibodies to HCV).
  18. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis.
  19. Has history of chronic or acute severe neurologic condition. Including: Neurologic and Neuroinflammatory Disorders: ADEM, including site specific variants, Cranial Nerve Disorders (including paralyses/paresis), GBS (including Miller Fisher Syndrome and other variants), Immune-mediated Peripheral Neuropathies and Plexopathies, Optic Neuritis, Multiple Sclerosis, Narcolepsy, Transverse Myelitis, meningitis, or meningoencephalitis.
  20. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
  21. Seropositivity or cross-reactivity to Chikungunya virus, Zika virus or Dengue virus on screening tests.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04440774


Contacts
Layout table for location contacts
Contact: Lorena Preciado-Llanes, PhD +44 1865 287819 chika01.safety@ndm.ox.ac.uk
Contact: Gabriella Mondini, MSc

Locations
Layout table for location information
Mexico
Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León.
Monterrey, Nuevo León, Mexico, 64460
Sponsors and Collaborators
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Abiel Homero Mascareñas de los Santos, MD Hospital Universitario "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT04440774    
Other Study ID Numbers: CHIKA01
First Posted: June 22, 2020    Key Record Dates
Last Update Posted: September 24, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Oxford:
Vaccine
ChAdOx1
Chikungunya
Zika
Mexico
Additional relevant MeSH terms:
Layout table for MeSH terms
Chikungunya Fever
Virus Diseases
RNA Virus Infections
Alphavirus Infections
Togaviridae Infections